The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chronic pain, epilepsy, and inflammatory conditions.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

As patients increasingly turn to cannabis for chronic pain, clinicians grapple with mixed evidence and a lack of high-quality ...

SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Even daily use of low-level cannabis does not have a negative impact on cognition in older adults, recent research finds.

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

It interacts primarily with CB1 receptors, affecting mood, memory and appetite. CBD is a major non-psychoactive cannabinoid that may affect anxiety, pain and inflammation and reduce seizures.

In recent years, the demand for natural remedies has surged, particularly those that address common health concerns like ...

Novel research has revealed that adolescent vaping of current delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and ...